Trial Profile

A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2025 According to an Atea Pharmaceuticals, Inc. media release, company to host a hepatitis C virus (HCV) key opinion leader (KOL) panel to discuss results of this study on Wednesday, May 14, 2025 at 10:00 AM ET.
23 Apr 2025 According to an Atea Pharmaceuticals, Inc. media release, full results from the Phase 2 clinical study will be presented at at the European Association for the Study of the Liver (EASL) Congress 2025 from May 7th-10th in Amsterdam, Netherlands.
09 Apr 2025 Results (n=256) presented in the Atea Pharmaceuticals Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com